600 patients67,035 observations120 daysLIVE

Patient P-01625

Synthetic patientNBL-101 · Day 119 · 45–54 · M · baseline S09Steering view · 3DOpen companion preview
Is the drug working?

Therapy response 85 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 80%, therapy response 78 today; biology is not blocking the drug.

Is a side effect starting?

No side effect starting: gi toxicity 20, systemic toxicity 13, no drift from the model.

Still taking it?

8 of 8 scheduled doses in the last 60 days are biologically confirmed (100%). Dose signature: resting HR +5 bpm, HRV −9 ms.

last 8 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 126Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • Keep the current walking rhythm
  • 💊Take the scheduled dose as agreed with your care team
  • 💊No additional supplements this week
Adherence
94% stable

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-01625 is on day 119 of NBL-101 (SR, baseline S09): response declining, tolerance improving, GI favorable. Over 14 days response moved -6 and GI -2; discontinuation risk is 11%. The state is in the restoration basin, heading towards restoration.

Biology sets the gain: FUT2 non-secretor, Low microbial diversity; butyrate capacity 50/100, diversity 2.8. Pushing it down: 3 keystone species absent (-21.6), FUT2 non-secretor (-17.5), Clostridioides difficile 1.813% (LPS load) (-16.9). Pulling it up: Butyrate producers intact (+12.3). From the daily log: alcohol +2.9 GI next day, histamine +2.3 GI next day, fibre -1.8 GI next day, simple carbs +1.7 GI next day.

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Declining
Tolerance
Improving
GI state
Favorable
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
11%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (weekly infusion, day 1 of each 7-day cycle)
  1. Day 0 NBL-101 startedBaseline state S09

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days
  • Inflammatory activity-6
  • Toxicity-5
  • Treatment adherence+4
  • Nutritional resilience-3
  • GI instability-2

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    GI burden
    Companion
    19.5/100
    worsening · +8.8 vs previous 14 d
    Toxicity
    Blood
    13.4/100
    worsening · +6.2 vs previous 14 d
    Sleep quality
    Wearable
    69.5/100
    stable · -1.7 vs previous 14 d
    Energy level
    Daily log
    6.1/10
    worsening · -0.6 vs previous 14 d
    Stress level
    Daily log
    2.5/10
    worsening · +0.3 vs previous 14 d
    Steps
    Wearable
    6,677
    worsening · -317 vs previous 14 d
    Adherence
    Companion
    94.4 %
    stable · +2.7 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards restoration · 85 from the failing basin, 2 from restoration.

    Would help
    • No untried action with strong evidence. Compose one from primitives.
    • More fibre
      GI -1.8 next day on high-intake days · n 17
    Would not help
    • Keep alcohol low
      GI +2.9 next day on high-intake days · n 21
    • Keep histamine low
      GI +2.3 next day on high-intake days · n 14
    • Keep simple carbs low
      GI +1.7 next day on high-intake days · n 20
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Alcohol
      +2.9detractor · 95%
    • Histamine load
      +2.3detractor · 79%
    • Insoluble fibre
      -1.8supporter · 61%
    • Simple carbohydrates
      +1.7detractor · 68%
    • Dietary fat load
      -1.3no signal · 32%
    • Spicy / capsaicin
      -0.6no signal · 19%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    46/100
    vs baseline (day 0)
    -19
    6 improved · 2 worsened
    synthetic signature · consistent with this patient's biology
    • 1 opportunist above range: Clostridioides difficile
    • 3 keystone species absent
    • Shannon 2.56 (expected ≥ 3)
    • 8 resistance genes
    • Tissue recycling index 42
    Pathogens / opportunists1/5
    from 3
    Keystone species3/8
    from 4
    Diversity1/2
    Metabolic modules0/4
    Vitamin synthesis3/7
    Oral translocation1/1
    Host DNA0/1
    Tissue recycling1/1
    Central mechanisms0/2
    from 2
    Virulence factors3/3
    from 4
    Antibiotic resistance genes8/8
    from 6
    Genetic predisposition2/2
    Opportunists above range
    Clostridioides difficile 1.813% AR
    Keystone species absent
    Akkermansia muciniphila, Bifidobacterium longum, Butyricicoccus pullicaecorum
    Capacity
    Shannon 2.56 · butyrate 619 CPM · SCFA 970
    3 vitamins below
    Host & mechanisms
    tissue recycling 42/100
    oral translocation 4.13% AR
    8 resistance genes · 3 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Mucosal barrier integrity 30
      • DNAFUT2 non-secretor lowers mucosal fucosylation
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • CYP2D6 Intermediate metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 2.8 · butyrate capacity 50/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisNormal
    • Bifidobacterium longumLow
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    62 ms
    Sleep
    8.0 h
    Steps
    6,715
    Resting HR
    59 bpm
    Daily log: GI score 20, nutritional resilience 61, adherence 94.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Keep fibre steady; no new sources this week
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Log the daily check-in; one line is enough
    • Keep the current walking rhythm
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0142850%S18DT-01improved82
    P-0148949%S05BR-03improved83
    P-0163847%S04GI-04improved83
    P-0162646%S04GI-04improved77
    P-0166444%S07CR-01improved85
    P-0176644%S01BR-03improved83
    P-0185542%S18GI-04improved76
    P-0152841%S20DT-01improved89
    P-0189638%S06CR-01improved73
    P-0171135%S03ME-01improved82
    P-0152232%S05HY-01improved56
    P-0164232%S07ME-01improved59